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Purpose: Human pluripotent stem cell (hPSC)-derived dopaminergic neuron progenitor cells 
(DAPCs) are a potential therapy for Parkinson’s disease (PD). However, their intracranial 
administration raises safety concerns including uncontrolled proliferation, migration and 
inflammation. Here, we apply a bimodal imaging approach to investigate the fate of DAPC 
transplants in the rat striatum. 
Procedures: DAPCs co-expressing luciferase and ZsGreen or labelled with micron-sized 
particles of iron oxide (MPIOs) were transplanted in the striatum of RNU rats (n = 6 per group). 
DAPCs were tracked in vivo using bioluminescence and magnetic resonance (MR) imaging 
modalities. 
Results: Transgene silencing in differentiating DAPCs accompanied with signal attenuation 
due to animal growth rendered the bioluminescence undetectable by week two post-intrastriatal 
transplantation. However, MR imaging of MPIO-labelled DAPCs showed that transplanted 
cells remained at the site of injection for over 120 days. Post-mortem histological analysis of 
DAPC transplants demonstrated that labelling with either luciferase/ZsGreen or MPIOs did not 
affect the ability of cells to differentiate into mature dopaminergic neurons. Importantly, 
labelled cells did not elicit increased glial reactivity compared to non-labelled cells. 
Conclusions: In summary, our findings support the transplantation of hPSC-derived DAPCs as 









































































Parkinson’s disease (PD) is a neurodegenerative disease that results in part from the progressive 
loss of dopaminergic (DA) neurons in the substantia nigra. Several groups have shown that 
human pluripotent stem cell (hPSC)-derived dopaminergic neuron progenitor cells (DAPCs) 
can generate mature DA neurons and improve motor function following intrastriatal 
transplantation in animal models of PD [1-2]. This has now evolved to the point that first in 
human hPSC-based DA neural transplants are being undertaken or planned in patients with PD. 
However, prior to undertaking larger-scale clinical studies, animal experiments are needed to 
adequately assess the safety of the therapies. Key safety concerns with such therapies for PD 
and other central nervous system (CNS) disorders includes the risk that the implanted cells 
could proliferate and form space occupying masses and/or migrate to off-target sites within the 
CNS, and/or induce major neuroinflammation [3]. In addition to considering the potential risks, 
it is also important to monitor the long-term viability and differentiation capacity of implanted 
cells, as to be effective they must differentiate into the appropriate phenotype and persist in the 
brain. 
An effective strategy for monitoring the proliferation, viability and localisation of 
implanted cells longitudinally is to employ a non-invasive imaging approach comprising 
different modalities, such as bioluminescence (BLI), magnetic resonance (MRI) and 
fluorescence imaging [4-5]. BLI is the most sensitive live animal imaging technique, enabling 
relatively small numbers of transplanted cells to be detected [6]. This technique requires that 
the cells express a luciferase reporter, which means that a signal is only emitted if the cells are 
alive. An increase in BLI signal over time indicates cell proliferation and potential tumour 
formation, whereas a loss of signal suggests that the cells are no longer viable. A drawback 




































































determine the location of the implanted cells and/or any resultant masses within the brain. MR 
imaging, on the other hand, has a very high spatial resolution, and can accurately map the 
position of intracranial lesions [7]. Moreover, by labelling cells prior to administration with an 
appropriate contrast agent, such as iron oxide particles [8] or 19F-based tracking agents [9], 
MRI can be used to plot the biodistribution of the cells over time. 
Hoehn and co-workers have shown previously that BLI and MR imaging can be used 
to monitor the viability and intracranial biodistribution of human embryonic stem cell (hESC)-
derived neural stem cells following implantation into the mouse striatum [10]. To the best of 
our knowledge, this bimodal approach has not previously been used to track the 
tumourigenicity, viability and biodistribution of hESC-derived DAPCs, following intrastriatal 
administration into the rat brain. A key aim of this study, therefore, was to assess the potential 
of this bimodal BLI/MR strategy to track hESC-derived DAPCs in vivo. In addition to 
evaluating the effectiveness of the imaging modalities themselves, we also investigated 
whether the labels used for tracking (i.e. a Firefly luciferase, FLuc-ZsGreen bicistronic vector 
for BLI and iron oxide particles for MR imaging [4, 11]) affected the differentiation potential 
of the cells and/or their immunogenicity following implantation into the rat striatum. 
 
Materials and Methods 
hESC culture and maintenance 
Clinical grade RC17 human embryonic stem cells (hESC) line were obtained from Roslin Cells 
Ltd., UK. Cells were expanded on laminin 521 (0.5 μg/cm2) (Biolamina) in iPS-Brew XF 
(StemMACSTM). Cells were passaged as small clumps using Versene, a non-enzymatic cell 




































































27632 dihydrochloride (StemMACS, Miltenyi) was added to the medium for the first 24 h after 
plating. Medium was changed daily and cells were maintained at 37°C under 5% CO2.  
  
Generation of hESC reporter line and labelling with iron oxide particles 
RC17 cells were transduced with a lentiviral vector encoding for the bicistronic expression of 
the codon optimised firefly luciferase (luc2) and ZsGreen (via an IRES link) under the 
constitutive promoter, elongation factor-α (EF1α). The vector plasmid was a gift from Bryan 
Welm (Addgene plasmid #39196) and the production and titration of viral particles was carried 
out using established protocols [11]. In order to transduce the hESCs, colonies of 
undifferentiated RC17 cells were dissociated into very small clumps consisting of about 10-15 
cells using Versene for 5 min. After centrifugation, the cells were counted and seeded onto 
laminin 521 at a density of approximately 2.5x104 cells/cm2 in the presence of 10 μM Y-27632. 
Cells were incubated overnight and transduced on the following day with 25x104 viral particles 
(multiplicity of infection of approximately 5) in the presence of polybrene (10 µg/mL). After 
24 h, the medium was replaced and the cells were expanded for 4 days prior to sorting for 
ZsGreen expression with a BD FACSAria (BD Biosciences) flow sorter. The Fluc-ZsGreen+ 
cells were collected in iPS-Brew culture medium supplemented with 10μM Y-27632, seeded 
on laminin 521 and expanded for subsequent experiments. To assess bioluminescence activity, 
cells were plated at different densities in black 96-well plates (Thermo Scientific), allowed to 
settle for 2-4 h and then incubated with medium containing D-luciferin (150 µg/mL, Promega) 
prior to data acquisition with an IVIS spectrum system (Perkin Elmer).  
Micron-sized particles of iron oxide (MPIO) were used as a label for MR detection of DAPCs. 
Suncoast Yellow MPIOs (Bangs Beads, 1.63 µm nominal diameter, Bangs Laboratories, Inc) 




































































μL for 24 h. After the labelling period, cells were carefully washed with PBS to remove 
unbound particles, harvested and then used for in vivo studies. The extent of MPIO labelling 
was assessed with a FACSCalibur (BD Biosciences) flow cytometer.  
 
Differentiation into neural precursors and mature neurons  
RC17 cells were differentiated toward mesencephalic dopaminergic progenitor cells (DAPC) 
or terminally differentiated into mature dopaminergic (DA) neurons as previously described 
[12]. In brief, DAPCs are obtained after neuralisation, patterning and expansion of the cells for 
a period of 16 days, whereas DA neurons are obtained via the maturation of DAPCs for 34 
days. Correct caudalization of progenitors towards a midbrain fate was achieved using 0.9 μM 
GSK3 inhibitor (CHIR99021).  
 
Cell implantation and in vivo imaging 
RNU rats (males, 5-6 weeks old) were purchased from Charles River and housed in 
individually ventilated cages under a 12h light/dark cycle, with ad libitum access to standard 
food and water. All animal experiments were performed under a licence granted through the 
UK Animals (Scientific Procedures) Act 1986 and were approved by the University of 
Liverpool ethics committee. All applicable institutional and/or national guidelines for the care 
and use of animals were followed. All procedures (surgical administration of cells and imaging) 
were carried out under isoflurane anaesthesia.  
Single-cell suspensions prepared in Hanks' Balanced Salt Solution were implanted 




































































reference, the skull was drilled at 0 mm anteroposterior and +/- 1.5 mm mediolateral, with each 
hemisphere receiving two deposits of cells at a depth of -5.0 and -4.3 mm from dura. Each 
deposit contained 75x103 cells in 0.75 µL of PBS, delivered with a microsyringe connected to 
an infusion pump. Rats were divided into three different experimental groups as outlined in 
Table 1.  
BLI was carried out with an IVIS spectrum system (Perkin Elmer). After inducing anaesthesia, 
the rats’ heads were shaved and the animals received an intraperitoneal injection of luciferin at 
a dose of 150 mg/kg body weight. Data was acquired 20 min post administration of the 
substrate with a field of view B (6.5 cm), medium binning, f-stop 1 and exposure time 
calculated automatically by the acquisition software, up to a maximum of 5 min. All 
bioluminescence data was normalised to the acquisition conditions and are displayed as 
radiance (photons/s/cm2/str). 
MRI data was acquired with a Bruker Avance III console interfaced to a 9.4T magnet system 
(Bruker Biospec 94/20 USR). RF excitation was achieved with an 86 mm resonator and signal 
detection with a 4-channel phased array receive-only rat brain coil. Once the injection site was 
located using scout images, higher resolution images were acquired with rapid acquisition with 
relaxation enhancement (RARE) sequence. Parameters: echo time (TE) = 38 ms, repetition 
time (TR) = 2700 ms, RARE factor = 8, number of excitations (NEX) = 8, field of view (FOV) 
= 35x35 mm, matrix size = 350x350 pixels, slices = 20, slice thickness = 500 µm. 
At the experimental endpoint, the rats received an overdose of pentobarbital and were perfused 
transcardially with PBS followed by 4% formaldehyde. The brains were harvested, postfixed 







































































Cells were washed twice with PBS and a minimum of 5x105 cells were lysed with TRI Reagent 
(Sigma). Total RNA was extracted according to the manufacturer’s protocol and a NanoDrop 
was used to determine RNA concentration. To synthesise cDNA, RNA was treated with 
DNase1 and reverse transcribed using random hexamers (Qiagen) and Superscript III reverse 
transcriptase (Invitrogen). PCR was performed on a CFX Connect system (Bio-Rad) using 
SYBR Green JumpStart Taq Ready Mix (Sigma). The genes OTX2, FOXA2 and LMX1A were 
measured to assess differentiation into DAPCs, with GAPDH being used as a housekeeping 
gene. Undifferentiated hESCs were used as a control. Relative expression levels of target genes 
between control and experimental samples were calculated using the 2-ΔΔCt method [13]. 
Primer sequences are shown in ESM Table 1. 
 
Immunostaining and histology 
Cells were fixed with 4% formaldehyde for 20 min, permeabilised with 0.1% Triton X-100 for 
20 min and blocked with 1% bovine serum albumin (BSA) for 30 min. Cryosections (10 m) 
from fixed tissues were permeabilised and blocked as described above. Primary antibodies 
were diluted in 1:1 Triton X-100:BSA according to the dilution factors in ESM Table 2 and 
incubated for 24 h at 4°C. Secondary antibodies were diluted 1:1000 in 1:1 Triton X-100:BSA 
and incubated for 2h at room temperature. For immunofluorescence, cells were counterstained 
with DAPI. Images were acquired on a 3i spinning disk confocal microscope CSU-X1 
(Intelligent Imaging Innovations) and processed with ImageJ [14]. For immunohistochemistry, 
tissue sections were incubated with 1.4 mM 3,3′-Diaminobenzidine (DAB), 0.01% hydrogen 





































































hESC labelling does not negatively impact on differentiation towards DAPCs or mature 
dopaminergic neurons in vitro 
Flow cytometry analysis of RC17 hESCs 4 days after viral transduction showed that 
approximately 47% of the population expressed the reporter gene ZsGreen (ESM Fig. 1a, b). 
After sorting, a pure population of hESCs expressing the reporter was obtained (Fig. 1a, b); 
herein defined as Fluc-ZsGreen+ hESCs. Fluc-ZsGreen+ hESCs maintained expression of 
ZsGreen over multiple passages and were morphologically indistinguishable from non-
transduced cells (Fig. 1a, b). To assess whether the introduction of the reporter affected 
pluripotency, embryoid bodies (EB) were generated and immunostained for markers of 
embryonic germ layer derivatives. The presence of GATA6 (endoderm), Brachyury 
(mesoderm) and Nestin (ectoderm) confirmed that the Fluc-ZsGreen+ hESCs remained 
pluripotent (ESM Fig. 1c). 
DAPCs were assessed for the co-expression of the key markers FOXA2, LMX1A and 
OTX2 on day 16 of differentiation. Quantification of mRNA via RT-qPCR revealed significant 
upregulation of all these markers (Fig. 1c), which was confirmed via immunofluorescence (Fig. 
1d). However, fluorescence microscopy also revealed that not all cells expressed ZsGreen after 
differentiation into DAPCs (Fig. 1d). DAPCs were further differentiated into mature DA 
neurons and immunostained (differentiation day 50) to detect the classic DA neuron marker, 
tyrosine hydroxylase (TH).  Immunofluorescence demonstrated that the transduced RC17-
derived DA neurons expressed TH (Fig. 1e) but ZsGreen was no longer detectable at this 




































































Flow cytometric analysis of DAPCs showed that only 51% of these cells expressed 
ZsGreen, implying a significant loss of reporter gene expression when compared to 
undifferentiated hESCs (Fig. 1f), and complete loss once the cells had matured to dopaminergic 
neurons (DAs) (Fig. 1e). Measurement of the light output (bioluminescence) revealed that the 
expression of luciferase corresponded to that of ZsGreen; that is, bioluminescence was strong 
before differentiation (37 p/s/cell), significantly reduced as cells differentiated towards DAPCs 
(17 p/s/cell) and extremely weak when they became mature DAs (< 1 p/s/cell) (Fig. 1g). 
Taken together, these results show that the introduction of the genetic reporter did not 
affect hESC pluripotency, nor their ability to differentiate to DAPCs and DA neurons. 
However, reporter gene expression was progressively lost as the cells differentiated towards 
DA neurons. Despite the reduction in light emission in DAPCs, we reasoned that it would still 
be possible to detect them in rodents in vivo, enabling their tracking and assessment of 
viability/tumorigenicity in the early post-transplant period, but that it would not be possible to 
detect the mature DA neurons.   
 
In vivo imaging reveals absence of DAPC tumorigenicity and long-term intracranial 
distribution. 
In addition to  assessing the ability of BLI and MRI to detect the implanted cells, a further 
objective of the in vivo studies was to investigate whether the presence of either the Fluc-
ZsGreen reporter or the MPIOs affected (i) the tumourigenicity of the cells, (ii) the ability of 
the hESC-derived DAPCs to differentiate into mature DA neurons in vivo, or (iii) the 
immunogenicity of the human cells. To this end, three groups of rats were set up. Group 1, 
which served as a control group for tumour formation, comprised of three rats that had Fluc-




































































(Fig. 2a); Group 2 comprised of six rats that had DAPCs derived from Fluc-ZsGreen+ hESCs 
implanted into the right striatum, and unlabelled cells into the left striatum (Fig. 2d); Group 3 
comprised 6 rats that had MPIO-labelled hESC-derived DAPCs implanted into the right 
striatum, and unlabelled hESC-derived DAPCs implanted into the left striatum (Fig. 4c). 
 
hESCs and DAPCs follow distinct fates in vivo, irrespective of the introduction of a 
reporter gene 
Optical imaging of animals that received undifferentiated hESCs on the administration day and 
on days 14 and 27 post-administration revealed great variability in the bioluminescence signal. 
On the administration day, just one of the animals displayed a signal, which was very weak, 
suggesting that Fluc expression was not robust enough for sensitive detection in all animals. 
Bioluminescence was progressively lost from this rat but detected in a different animal at a 
later time point (ESM Fig. 2a).  
MR imaging of these rats at the experimental endpoint (day 27) displayed a large area 
of atypical hyperintense contrast surrounding the injection site, which was present in both brain 
hemispheres of all animals (Fig. 2b and ESM Fig. 2b). Histological analysis of the tissue 
showed that this area consisted of a large number of tightly packed cells as evidenced by strong 
nuclear (haematoxylin) staining in the same area (Fig. 2b), suggesting an abnormal growth of 
cells. Immunofluorescence microscopy of these samples revealed that the masses in both 
hemispheres consisted of human cells, as evidenced by positive staining for a human specific 
nuclear antigen (hNuclei). Interestingly, however, not all cells in the masses that formed in the 
right brain hemisphere (Fluc-ZsGreen+ hESCs) expressed ZsGreen, suggesting that some of the 
hESCs lost expression of the reporter (Fig 2c). The hESC-derived masses did not display a 




































































shown). Instead, many of the cells expressed β-III tubulin, suggesting that transplantation of 
these cells in the rat brain promoted differentiation to ectodermal lineages (ESM Fig. 2c). The 
growths were also negative for OCT4, confirming that cells had differentiated in the brain 
(ESM Fig. 2d). Taken together, these results indicate that undifferentiated hESCs form mass 
lesions, irrespective of the introduction of the Fluc-ZsGreen reporter. 
For rats implanted with DAPCs (group 2) (Fig. 2d), 4 of 6 animals displayed a 
bioluminescence signal on the administration day (Fig. 2e and ESM Fig. 3a), which was not 
detectable at the subsequent imaging points (days 14, 28, 56 and 91). In contrast to hESCs, 
administration of DAPCs resulted in no abnormal MR contrast at the experimental endpoint 
(day 91, Fig. 2f), with all animals exhibiting normal brain structures and the needle track being 
the only remarkable feature.  
Human cells were still present at the injection site in both hemispheres, as evidenced 
by hNuclei positivity (Fig. 3a). Importantly, the areas containing human cells were also positive 
for TH, suggesting maturation of some DAPCs in the rats’ brains within the experimental 
period (91 days). Not all human cells robustly expressed TH, likely because a period of >20 
weeks is necessary for the maturation of all DAPCs. The injection sites were also positive for 
a human-specific NCAM (hNCAM) antigen (Fig. 3b), providing further evidence that human 
cells had integrated with the rat brain and displayed neural lineage commitment, irrespective 
of whether they had been genetically modified.  
  
MPIO labelling enables assessment of the intracranial distribution of implanted cells 
Flow cytometry analysis of MPIO-labelled DAPCs suggested that approximately 72% of 




































































MPIOs (Fig. 4a). We also detected a shift in the side scatter of DAPCs after labelling with 
MPIOs, providing further evidence for the internalisation of the particles (Fig. 4b). 
Rats implanted with MPIO-labelled DAPCs (group 3) (Fig. 4c) were imaged only via 
MR, as neither of the hemispheres received cells with the genetic reporter. Monitoring of this 
group for up to 4 months post implantation confirmed that DAPC implantation does not lead 
to tumour formation, with all rats displaying normal brain structures at all time points. In 5 out 
of 6 rats, hypointense contrast was seen in the right brain hemisphere (Fig. 4d and ESM Fig. 
3b). This was an expected consequence of the MPIO labelling, which enabled us to monitor 
the delivery and intracranial distribution of DAPCs. Remarkably, the distribution of the 
administered DAPCs appears to remain stable throughout the 4 months that the animals were 
monitored for, with no obvious change in the area with hypointense contrast, suggesting that 
the DAPCs were confined to the areas into which they were initially deposited. In one rat, no 
hypointense contrast was observed in the target area. Further analysis of the scans revealed that 
for this animal, the needle had been inserted at an angle, with the cells delivered to the ventricle 
leading to them becoming lodged at a different anatomical location (ESM Fig. 3c). 
  
As observed before, immunofluorescence staining at the injection sites confirmed the presence 
of human cells that expressed TH, reinforcing the point that these cells were able to integrate 
within the rat brain and differentiated into mature DAs, irrespective of the MPIO labelling (Fig. 
4e). In the right hemisphere, MPIOs were found in the same areas as the administered human 
cells and appeared to localise to perinuclear regions. 
  




































































A previous study showed that the implantation of Fluc+ hESC-derived neural stem cells into 
the mouse striatum caused marked glial reaction in the host brain, as evidenced by intense 
immunostaining for glial fibrillary acidic protein (GFAP), a marker of reactive astrocytes11. To 
investigate whether Fluc-ZsGreen or MPIOs contributed to this reaction, sections from group 
2 and group 3 rats were immunostained for GFAP. Qualitative analysis showed an increase in 
GFAP staining around the human implants, but no differences in staining intensity were 
observed around implants comprising unlabelled human cells or MPIO-labelled cells (Fig. 5a 
and ESM Fig. 4a) and cells derived from Fluc-ZsGreen+ hESCs (Fig. 5b and ESM Fig. 4b). 
Consistent with the expression profile of ZsGreen in mature DA neurons in vitro (Fig. 1e), 
expression of ZsGreen in brain sections was barely detectable (Fig. 5b and ESM Fig. 4b). 
 
Discussion 
Our study assessed the effectiveness of BLI and MR imaging to monitor the tumourigenicity, 
viability and intracranial biodistribution of hESC-derived DAPCs following stereotactic 
injection into the rat striatum. In most animals, BLI could only detect Fluc-ZsGreen+ cells 
shortly after administration and was not effective for monitoring tumourigenicity and cell 
viability in the longer-term. MR imaging, on the other hand, could detect tumours arising from 
undifferentiated hESCs and could monitor the intracranial biodistribution of MPIO-labelled 
hESC-derived DAPCs over the full time-course of our experiments. 
The inability to detect cells with BLI likely resulted from a number of factors. First, at 
the initial imaging session, the rats were only 6 weeks old. During the intervening two weeks 
before the next imaging session, the rats grew considerably and became more pigmented (see 
ESM Fig. 3a), causing the intensity of the emitted light to be reduced; this likely explains why 




































































ZsGreen+ hESC-derived mass (ESM Fig. 2a, rat 3). Bernau et al found that Fluc+ human foetal 
neuronal progenitors implanted into the rat striatum could be imaged with BLI for 3 months 
[15]. However, they implanted 9x105 Fluc+ cells into the left hemisphere compared with only 
1.5x105 cells in our study. An additional problem was that in comparison with undifferentiated 
hESCs, we found that the expression levels of the reporter genes decreased by ~50% in Fluc-
ZsGreen+ hESC-derived DAPCs, and could not be detected at all in the mature DA neurons. It 
is well recognised that ESC differentiation is accompanied by increased levels of DNA 
methylation, leading to gene silencing, and that the pattern of silencing is cell type specific 
[16]. The choice of promoter also affects the extent of silencing. A previous study comparing 
the activity of five constitutive promoters, EF1α, human β-actin (ACTB), cytomegalovirus 
(CMV), phosphoglycerate kinase (PGK) and ubiquitinC (UbC) in differentiating hESCs, 
reported that EF1α was the most stable, with expression levels in EBs being reduced to ~50% 
of those in undifferentiated hESCs [17]. Our observation that Fluc-ZsGreen expression was 
undetectable in the mature DA neurons, both in vitro and in vivo, was unexpected. Tennstaedt 
et al have shown that a EF1α:Fluc-GFP+ neural stem cell line derived from hESCs could be 
detected with BLI for 6 weeks following injection into the mouse brain without any noticeable 
decrease in bioluminescence intensity [18]. However, the neural stem cells used in the 
Tennstaedt study have a different phenotype to hESC-derived DAPCs and there is no evidence 
that they differentiate into the DA lineage[18]. Likewise, there is no evidence that the Fluc+ 
human foetal neuron progenitors used in the aforementioned Bernau et al study differentiate 
into the DA lineage in the rat brain [15]. Indeed, as far as we are aware, there are no studies 
that show Fluc expression in hESC-derived DA neurons in vivo when Fluc is under the control 
of a constitutive promoter. In future studies, a cell type-specific promoter, such as FOXA2, 
which is expressed in both DAPCs and mature DA neurons [19], could prove more effective 




































































highly sensitive AkaLuc luciferase in combination with the substrate Akalumine [20]. 
However, one advantage of our system is that the loss of signal is due to differentiation. This 
could be used to show that the grafted cells have indeed followed the correct pathway post 
implantation rather than dedifferentiated back into an ESC-like phenotype.    
Four weeks after implantation of undifferentiated hESCs, MR imaging could detect a 
cell mass in both cerebral hemispheres, irrespective of whether the cells had been transduced 
with the Fluc-ZsGreen reporter (ESM Fig. 2b). However, no cell masses were detected at any 
time point following administration of hESC-derived DAPCs, suggesting that in contrast to the 
undifferentiated hESCs, the DAPCs are non-tumourigenic. Cells labelled with MPIOs could 
be detected at all time points using longitudinal MR imaging. In addition, we found that the 
cells remained at the injection site and did not appear to migrate to other brain regions. From a 
safety perspective, the lack of migration is important to prevent cells integrating into intact 
neural circuits causing side effects (e.g. epilepsy) [21]. 
Previous studies have shown that labelling cells with iron oxide nanoparticles can 
inhibit differentiation to specific lineages [22-23]. In our study, we did not find any evidence 
that the bicistronic Fluc-ZsGreen reporter or the MPIOs inhibited the differentiation of hESC-
derived DAPCs into TH+ DA neurons. The final aim of our study was to investigate whether 
the reporter or the MPIOs increased glial reactivity to the grafted cells. It is known that the 
implantation of cells into the brain induces a glial response [24], as evidenced by increased 
numbers of reactive GFAP+ astrocytes surrounding the grafts [10]. Transplantation of both 
labelled and unlabelled DAPCs elicited a marked glial reaction at the injection site, as expected. 
However, there was no notable difference in the scale of glial response, suggesting that neither 





































































Conclusions   
In summary, we have demonstrated that hESC-derived DAPCs can be labelled with 
luminescence and contrast-enhancing reporters for in vivo cell tracking. Following intracranial 
transplantation in the rat striatum, our findings support the safe implementation of DAPC-
derived therapies for the treatment of PD. 
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Figure Legends  
Figure 1. Effect and stability of the Fluc-Zsgreen reporter gene in hESCs. (a) Phase 
contrast and fluorescence microscopy of control and Fluc-ZsGreen+ hESCs. Cells were imaged 
3 passages post sorting. (b) ZsGreen expression, as measured via flow cytometry, of control 
and sorted hESCs. The green fluorescence of sorted cells is stable for several passages. (c) 
Expression of OTX2, FOXA2 and LMX1 in DAPCs obtained from Fluc-ZsGreen+ hESCs. (d, 
e) Fluorescence microscopy of DAPCs and DAs obtained from Fluc-ZsGreen+  hESCs 
(differentiation days 15 and 50 respectively). Cells were immunostained for OTX2, FOXA2, 
LMX1A and TH. (f) Flow cytometry shows that differentiation into DAPCs reduces ZsGreen 
expression (approx. 47% of the cells expressing the construct). (g) BLI of different numbers of 
Fluc-ZsGreen+ hESCs, DAPCs, and mDAs and the corresponding photon flux. Data are 
representative of three independent experiments. Error bars represent SD and the solid line the 
linear fit of the data. Scale bars in micrographs correspond to 100 μm. 
 
Figure 2. Long-term fate of hESCs and DAPCs. (a) Schematic of injection and experimental 
timeline of hESC administration and imaging (b) Representative RARE MRI scan (day 27) 
and corresponding histological section (H&E staining) of a rat that received undifferentiated 
hESCs (left hemisphere: non-transduced, right hemisphere: Fluc-ZsGreen+). Both sides display 
a large area of hyperintense contrast at the injection site (arrowheads) which was confirmed to 
correspond to tightly packed cell nuclei via histology. (c) Fluorescence microscopy of areas of 
abnormal growth in the right hemisphere. In all cases the growth corresponded to cells of 
human origin, as evidenced by expression of a human nuclear antigen. The level of ZsGreen 
expression was heterogeneous within the growths, with areas of strong expression (top) and 




































































experimental timeline of DAPC administration and imaging (e) BLI of two of the six rats that 
received DAPCs as imaged on days 1, 14 and 91. Most, but not all rats displayed a signal on 
the injection day, but this was lost by day 14 and no signal was seen up at any other time points. 
Left panel is representative of rats that displayed signal on day 1, and the right panel 
representative of rats that did not display a signal in any of the days. Data for the other rats and 
time points are shown in the SI. Note that this rat strain can display cycles of thin hair growth, 
as seen in some images. (f) RARE MRI scans (day 90) of all 6 rats that received DAPCs (left 
hemisphere: non-transduced, right hemisphere: Fluc-ZsGreen+). No abnormal features are 
seen, apart from the needle track that is still visible in some animals (indicated arrowheads in 
the first rat only). 
 
Figure 3. DAPC integration with the rat brain. (a) Immunofluorescence microscopy of the 
injection sites (left hemisphere: non-transduced, right hemisphere: Fluc-ZsGreen+). Cells 
express a human nuclear antigen, showing that the DAPCs survived in the rats’ brains and 
expressed TH, suggesting that they matured into DAs. Arrowhead indicates a human cell 
strongly expressing TH. (b) Immunofluorescence of a similar area but using an antibody 
against human NCAM as a means to confirm the human origin of the cells. Scale bars 
correspond to 50 µm. 
 
Figure 4. MPIO tracking of DAPCs in the rat brain. (a) Yellow fluorescence of unlabelled 
and MPIO-labelled DAPCs. (b) Forward vs. side-scatter plot of unlabelled and MPIO-labelled 
DAPCs. (c) Schematic of injection and experimental timeline of DAPC administration and 
magnetic resonance imaging (d) Representative RARE MRI scans of a rat that received MPIO-




































































14, 28, 42, 70 and 126 post-administration. Hypointense contrast, indicative of a reduction in 
relaxation time as caused by MPIO labelling, is seen in the right hemisphere throughout the 
experimental period (indicated with an arrowhead in the first image). No abnormal growth is 
observed in either of the hemispheres. (e) Immunofluorescence microscopy of the injection 
sites. Cells express human NCAM, showing that MPIO-labelled DAPCs survived in the rats’ 
brains and TH, suggesting that DAPCs matured into DAs.  MPIO-specific fluorescence is only 
seen in the right hemisphere, and tends to be localised to near the cell nuclei. Note that the 
MPIO fluorophore, Suncoast Yellow, is excited at 405 nm and bleeds into the DAPI channel. 
Scale bar = 50 µm. 
 
Figure 5. Glial reaction at the injection sites. (a) Immunofluorescence microscopy of brains 
from rats that received MPIO-labelled DAPCs (left hemisphere: unlabelled; right hemisphere: 
labelled). The presence of human cells is identified with hNCAM staining, and the intensity of 
GFAP staining is stronger in these areas. MPIOs are only seen in the right hemisphere. (b) 
Immunofluorescence microscopy of brains from rats that received Fluc-ZsGreen+ DAPCs (left 
hemisphere: untransduced control cells; right hemisphere Fluc-ZsGreen+ cells). Scale bars 










































































Table 1. Description of the experimental groups.  
Group Cells implanted in left 
hemisphere 





1 Undifferentiated hESCs Undifferentiated hESCs 
(Fluc-ZsGreen+) 
3 day 27 
2 DAPCs DAPCs 
(Fluc-ZsGreen+) 
6 day 91 
3 DAPCs DAPCs 
(MPIO-labelled) 
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Response to reviewers’ comments 
Re: “Assessing human embryonic stem cell-derived dopaminergic neuron progenitor 
transplants using non-invasive imaging techniques” by Mousavinejad et al. 2020  
 
Reviewer #1: In this study the authors trying to show the longevity and fate of implanted hESC before 
and after differentiated into DAPC and DA in the striatum of Rat by longitudinal assessment. They used 
cells labelled with luciferase (for bioluminescence imaging) and micro-sized iron oxide (MPIO) 
particles (for MR-Imaging) as reporters for dual imaging in vivo. The comparison of cell viability before 
and after differentiation into DAPC and DA compared to hESC were systematically evaluated in vitro 
and in vivo in rat after implantation. They evaluated the growth, differentiation and teratoma formation 
several weeks after implantation of hESC and DAPC and observed that there is no big difference 
between the cells with and without reporters. It is a simple but an useful study which can be considered 
for publication after addressing the following minor comments. 
 
We thank the reviewer for these comments.  
 
 
1. It has been well established in the literature that more than 50% of the implanted cells (either 
syngeneic or xenograft) tend to lose their viability within first 48 hrs and the rest over time based on 
the host immune system's impact on the implanted cells. BLI is a viability imaging reporter while MR 
contrast agent can stay in the implanted location even several days after the cells dye. In contrast BLI 
has poor spatial resolution and light attenuation by soft and hard tissues. Hence a combination of 
these two imaging reporter would be important. The authors mention these issues in their introduction 
and discussion section of the manuscript, but tend to ignore in their experimental approaches where 
no assessment for cell viability has been performed. The authors should consider evaluating at least 
the end point ex vivo analysis for cell viability. 
 
We agree with the reviewer that assessing transplants longitudinally using BLI would have 
been ideal to assess graft viability. As discussed in the manuscript, loss of transgene expression 
and attenuation of the bioluminescence signal after DAPC administration meant that this was 
not possible. However, we have shown that transplanted human cells were alive at the 
experimental endpoint in all groups via immunofluorescence, using human-specific antibodies 
against a nuclear antigen and NCAM (see Fig. 3, Fig. 4, Fig. 5 & ESM Fig. 4). By examining 
the entire volume of the transplant areas, it may have been possible to quantify the total number 
of viable cells in each group and compare this to the number of administered cells. However, 
quantifying the survival ratio of transplanted cells was not the primary goal of this project; 
rather, we were interested in the fate of those cells that survived.      
 
 
2.  It is not clear how the MPIO were taken-up by the cells. It is also important to show toxicity data 
for these microparticles in hESC cells. Normally the SPIO and IO were transfected in cells using some 
transfection agents. But in this study the authors just exposed cells to MPIO without any specific agent. 
Hence it is important to quantify the number of particles present inside the cells. 
Author’s Response to Reviewers‘ Comments Click here to access/download;Author’s Response to
Reviewers‘
 
We agree that SPIONs often require the use of transfection reagents for cellular uptake. 
However, as the reviewer points out, we have used magnetic particles of iron oxide (MPIOs) 
from Bangs Laboratories in this study. These MPIOs are coated with a polymer similar to that 
used in the manufacture of tissue culture vessels. This polymer matrix effectively shields the 
cell from the iron oxide core. As such, they do not require transfection reagents for endocytotic 
particle uptake and are generally non-toxic to cells. Bangs Laboratories MPIOs have been used 
previously to label murine pluripotent stem cell-derived neural progenitors with no observed 
cytotoxicity [1]. Furthermore, human mesenchymal stromal cells and foetal neural progenitors 
have been shown to behave normally following MPIO labelling [2]. Therefore, we do not 
believe that the MPIOs used in this study had any negative impact on labelled DAPCs, nor 
their behaviour in vivo. Indeed, we did not observe any qualitative difference in transplant 
viability when comparing MPIO-labelled DAPCs to controls (see Fig. 4e & ESM Fig. 4). 
Labelling efficiency was measured via flow cytometry (see Fig. 4a).  
 
 
3. The quality of all the images provided in the manuscript are very poor. It is important get high contrast 
images for all the immunostaining results. 
  
We thank the reviewer for bringing this to our attention. All figure panels were submitted at 
300 dpi. Unfortunately, the pdf conversion system significantly reduced this resolution. We 
will ensure that the publisher has high-resolution figures for the accepted manuscript. Further, 
we have attached high-resolution versions of all figures in a compressed file for inspection 
following resubmission.  
  
 
Reviewer #2: The submitted manuscript was very well written and the experiments were conducted and 
then discussed in an ideal manner including negative results (eg loss of BLI signal over 
time/differentiation) that would be pertinent to other researchers conducting similar research.  
 
We thank the reviewer for these comments. 
 
 
Minor comments:  
1. Some fluorescent reporter genes can be partially (or fully) quenched during fixation of tissues post 
mortem.  It may be wise to include this as a caveat when interpreting immunofluorescence 
histological data. 
  
We agree that tissue fixation and subsequent processing for histological analysis can lead to 
partial or complete quenching of fluorescent reporters. However, this caveat is typically 
associated with paraffin processing (specifically the dehydration step) rather than fixation [3]. 
In the present study, we have cryo-embedded the post-mortem samples, which better preserves 
fluorescence. Furthermore, we have observed fluorescent murine mesenchymal stromal cells 
in frozen sections when labelled using the same Fluc-ZsGreen lentiviral reporter [4]. We also 
showed that ZsGreen expression was maintained in some of the hESC-derived masses (see Fig. 
2c), supporting the notion that histological processing was not the cause of fluorescence loss. 
Based on our experience, we believe that the loss of ZsGreen fluorescence post-mortem was 
due to gene silencing as DAPCs matured (as stated in the discussion), rather than as a result of 
histological processing. We also note that although we have imaged all tissues in the green 
channel in order to assess ZsGreen expression, this was not the main method we employed to 
identify the human cells. For that, we used immunofluorescence employing human specific 
antigens (human nuclei and human NCAM).  
 
 
2. I am curious to why the authors chose to keep some of the individual IF microscopy channels in grey 
scale rather than use the colour representation as shown in the merged image.  The in vitro assessments 
and supplementary data used colour representation in the channel images.  I suggest authors display 
both the manuscript and supplemental images consistently and provide explanation to why using grey 
scale rather than colour is the optimal choice if chosen. 
 
We chose to show individual channels in greyscale because the human perception of colour is 
non-linear, meaning that grayscale images are easier to see and interpret than colour images 
[5]. However, we thank the reviewer for pointing out inconsistencies in our presentation of 
main text and supplementary figures. We have now changed individual colour images to 
greyscale in ESM Figs. 1 & 2.  
 
 
3. MPIOs can also persist in an area after uptake from bystander cells such as microglia or infiltrated 
peripheral macrophages.  To provide further evidence that the persistent MPIOs represent persistent 
cells of interest the authors could stain the tissues using Perls Prussian blue to detect the nanoparticles 
and perform IHC for glial or macrophage markers (eg GFAP) to look for bystander cell 
uptake.  Alternatively the cell masses could be dissected out post mortem, and assessed with flow 
cytometry using the fluorescence of the nanoparticles in concert with phenotyping antibodies (ie human 
marker vs GFAP or other glial/macrophage markers eg CD45/CD11b/CD11c etc). 
 
Whilst Prussian blue (PB) is a useful stain for nanoparticles composed of iron, the MPIOs used 
in this study are surrounded by a polystyrene matrix, meaning that PB staining would only 
identify MPIOs bisected during sectioning. This is supported by the fact that cells labelled with 
MPIOs from Bangs Laboratories do not stain positive for PB in monolayer culture [6]. As such, 
this approach would underestimate the number of MPIOs in the transplant areas, given that the 
particles are approximately 1.6 μm and cryo-sections are 7 μm.   
We agree that MPIO uptake by host immune cells is an issue of concern, which could lead to 
false positives. We have conducted co-staining of glial cells (GFAP) and DAPCs (hNCAM) in 
MPIO-labelled transplants (see Fig. 5a & ESM Fig. 4a) and we did not observe particles in 
glial cells. Indeed, MPIOs were localised to perinuclear regions of DAPCs and were not 
observed outside the transplant area.  
Flow cytometric quantification of MPIO uptake by bystander immune cells could indeed 
provide useful information on the specific localisation of MPIOs following transplantation, but 
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